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SUMMARY 
The expression of the two Epstein-Barr virus (EBV) major membrane proteins gp250/350 (MA-BLLFl) 
on the surface of recombinant CHO clones cannot be amplified by methotrexate (MTX) selection, perhaps due 
to toxic effects of these membrane proteins. After removal of sequences encoding the part of the glycoproteins 
responsible for membrane anchorage, the gp250/350 is secreted into the medium. Following selection with 
MTX, this construct allows the ~p~cation of the expression products. Besides the possible use of these 
proteins in protection experiments, they can also be used as antigens for diagnosis, which opens an efficient 
approach for control of EBV-related neoplasias by early therapy. 
INTRODUCTION 
Epstein-Barr virus (EBV) is a ubiquitous human 
y herpesvirus which causes mononucleosis after 
primary infection and persists lifelong in man. The 
virus is associated with two neoplasias: the EBV- 
positive Burkitt lymphoma and an undifferentiated 
form of NPC, which has a remarkably high incidence 
in some areas of South-East Asia. 
There are two possibilities for control of these 
neoplasias: either by early diagnosis and treatment, 
or by vaccination in an attempt o delay or modify 
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natural infection by EBV and possibly lower inci- 
dence rates. 
Candidates for a possible EBV subunit vaccine are 
two viral envelope glycoproteins with M,s of 250 000 
and 350000 (Epstein et al., 1985). Both proteins are 
encoded by the same viral reading frame, BLLFl 
(Beisel et al., 1985), and are frequently addressed as 
MA-BLLFl or gp250/350. The size differences are 
caused by a partial splice event which removes an 
internal part of the mRNA encoding gp350 to yield 
a smaller transcript, which in turn encodes gp250 in 
the same frame. More than half of the M, is 
contributed by glycosyl residues. Recently we 
reported the synthesis of these glycoproteins in CHO 
using a vector which combines a dhfr gene together 
with the MA gene and eukaryotic regulation signals 
(Motz et al., 1986~). 
The produced MA proteins were anchored in the 
membranes of the CHO and have an A4, slightly 
lower than that coded by the EBV-producing B95-8 
cells. This may result from a different extent of 
glycosylation. 
We attempted to amplify the recombinant se- 
quences by MTX selection and, by doing so, increase 
expression. However, in our hands it was not possi- 
ble to obtain clones which were able to overcome the 
MTX inhibition by amplification of the dhfr gene. 
This finding and the very low rate of successfully 
transfected cells made us assume that the integration 
of the foreign viral glycoproteins into the CHO cell 
membrane may become toxic when reaching certain 
levels. 
EXPERIMENTAL AND DISCUSSION 
(a) Construction of a eukaryotic expression plasmid 
coding for a truncated version of gp250/350 
To prevent the integration of the glycoproteins 
into the cell membrane we removed gp250/350 
sequences responsible for the membrane anchorage. 
Chou and Fasman (1978) predictions of the second- 
ary structure, superimposed with values for hydro- 
philicity or hydrophobicity, predict a hydrophobic 
stretch with a b-sheet structure near the C terminus 
of the protein (Motz et al., 1986a). This part of the 
protein is believed to be responsible for membrane 
anchorage (Beisel et al., 1985) and the corresponding 
sequences were removed to allow secretion of 
gp250/350. 
A PstI site immediately 5’ of the transmembrane 
region was used for the construction of the truncated 
version shown in Fig. 1. Downstream from this PstI 
site a short oligodeoxynucleotide encoding a trans- 
Fig. 1. Construction of the expression plasmid pMDIIIGPTR. The plasmid pUCLP1.9 (upper part, left; Motz et al., 1986a) contains 
the 1.9-kb PstI fragment ofthe MA-BLLFlgp250/350 coding region (a detailed map is given in Motz et al., 1986~); the 3’ end is located 
next to the Hind111 site of the pUC-vector. By insertion of the 1867-bp EcoRI-PsrI-fragment from this plasmid into the EcoRI + PstI-cut 
vector pUCARG601 (containing a fragment of the ep138 EBV gene and a short synthetic oligodeoxynucleotide; Motz et al., 1986b), 
the gp250/350-coding region lacking the sequences coding for membrane anchorage is terminated now by the oligodeoxynucleotide 
coding in frame for five arginine residues and two stop codons. For insertion into the eukaryotic expression vector pMD1 (Motz et al., 
1986c), it was necessary to generate a Sal1 site at the 3’ end of the gene. This was achieved by insertion of the 1896-bp EcoRI-Hind111 
fragment from pUCLP1.9-2 into the EcoRI + HindIII-cut vector pINIIIA1 (Masui et al., 1984), isolation from pINLP1.9 as 1902-bp 
EcoRI-BarnHI fragment and ligation withEcoRI-BumHI-cut pUC8 (Vieira and Messing, 1982). The resulting plasmid pUCLP1.9-3 now 
contains the 3’ part of the MA gene followed by the synthetic oligodeoxynucleotide and a Sal1 site. The complete MA gene in pUC18GP 
(Motz et al., 1986~) was inserted into pUC8 as a BumHI-Sal1 fragment and the resulting plasmid pUC18GPS was cut with NcoI + Sal1 
which removes the 3’ part of the MA gene. This part was replaced by the 1155-bp NcoI-Sal1 fragment from pUCLP1.9-3 to obtain 
pUC18GPTR now containing a truncated MA gene. 
This truncated version ofthe MA gene was combined with the vector pMDI as a 2640-bpXbuI-Sal1 fragment. In the resulting plasmid 
pMDIGPTR the MA gene is now located downstream from the SV40 early promoter and /I-globin splice donor and acceptor sites. In 
a final step, pMDIGPTR was linearized by Sal1 and combined with a 2200-bp Sal1 fragment from pUCSVDH carrying the dhfr gene 
and transcriptional regulation signals (SV40 enhancer, major late Ad promoter and splice donor signal; a splice acceptor signal and 
the SV40 polyadenylation signals; Kaufman and Sharp, 1982). In the resulting vector pMDIIIGPTR the dhj? cassette has an orientation 
such that the SV40 polyadenylation signals are next to the MAgene and should terminate both the MA and dhfr transcripts. 
Abbreviations: ORI, origin of replication; ApR, /%lactamase gene. B, BumHI; E, EcoRI; H, HindHI; N, NcoI; P, PsrI; S, SalI; Ss, SstI; 
X. XbuI. 
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Fig. 2. Northern blot analysis of transcripts in recombinant 
CHO clones. 10 pg RNA obtained according to Chirgwin et al. 
(1979) and pelleted through CsCl(l.8 g/ml) was electrophoresed 
on a 1 y0 agarose gel in MOPS buffer and in the presence of 6% 
formaldehyde. After transfer to nitrocellulose, EBV-specific 
transcripts were hybridized with [32P]pUC18GP in 50% for- 
mamide, 5 x SSC and 2 x Denhardt’s olution at 50°C for 20 h. 
The filter was washed 4 x 5 min with 2 x SSC and 0.1% SDS 
at room temperature and 2 x 15 min with 0.1 x SSC and 0.1 y0 
SDS at 68°C and exposed to an x-ray film filter for 48 h. Lanes 
‘pMDIIIGP’ and ‘pMDII1’ contain RNA of the CHO clones with 
the membrane-anchored version (barely visible; Motz et al., 
1986~) and the negative control. pMDIIIGPTR originates from 
a clone which secretes the EBV proteins into the medium. 
‘pMDIIIGPTR-10 nM MTX’ shows the transcripts of a clone 
after amplification with 10 nM MTX. The following three lanes 
show the gp250/350-specific RNA from clones amplified with 
lational stop codon was inserted. The sequences 
were combined in the steps shown in Fig. 1 to obtain 
the plasmid pMDIIIGPTR. 
In comparison with the vector used for membrane- 
anchored expression (Motz et al., 1986c), the &jr 
gene and its regulation signals are now inverted. This 
brings the SV40 polyadenylation signals next to the 
3’ end of the EBV glycoprotein sequences. The poly- 
adenylation of the early and late transcripts are 
located in the same area in reverse orientation on the 
SV40 genome. For that reason both transcripts, from 
the dhfr gene as well as from the glycoprotein 
sequence, should now be terminated by the same 
SV40 fragment. 
Following transfection (Graham and Van der Eb, 
1973) and selection of CHO in MEM a - medium, 
many clones have been isolated without difficulty, as 
was seen with the membrane-anchored MA clones. 
None of the clones showed membrane fluorescence, 
but in six of eight culture supernatants tested the 
membrane protein was detectable. 
(b) Sequence amplification 
Amplification through MTX selection was now 
possible. After selection with 10 nM MTX, colonies 
were isolated and further amplified with 20 nM 
MTX. From these colonies two individual clones 
were isolated and the remaining colonies were 
pooled. 
After two months in culture, the mRNA of these 
cell lines was analyzed in Northern blots (Fig. 2). 
With labeled gp250/350-specific probes, two bands 
of 2.6 kb and 3.2 kb can be detected, resulting from 
a partial splice event and corresponding to both 
gp variants. Compared to CHO cells without MTX 
selection a strong increase of the gp250/350+pecitic 
mRNA can be observed through the amplification 
procedure. The transcripts have nearly the same size 
as the mRNA from the CHO clone with the mem- 
20 nM MTX. ‘pMDIIIGPTR-1’ and ‘-2’ were clones individually 
isolated after 20nM MTX selection; ‘pMDIIIGPTR-P’ was 
obtained by combining all remaining clones from amplification 
and maintenance in culture for two months. As in 
CHO[pMDIIIGP], the truncated MA versions are also partially 
spliced and have nearly the same size, indicating that the SV40 
polyadenylation signal is used for termination. The sizes of EBV- 
specific transcripts are indicated in kb on the figure. 
B 
Fig. 3. Secretion of the truncated gp250/350 versions. 
(Panel A) Immunostained Western blot showing secreted gp250 
and gp350 in the supematant of the recombinant CHO clones. 
Proteins of 30 ml of culture medium (MEM a - (Gibco); 10% 
fetal calf serum) from cells grown to confluence and maintained 
for 3 days were precipitated by 70% ammonium sulfate and 
dissolved in 3 ml of 20 mM Tris . HCl pH 7.5. 15 ~1 were loaded 
onto an SDS-lo% polyacrylamide gel, the proteins electro- 
phoresed and transferred to nitrocellulose. EBV-related proteins 
were detected by incubation with an NPC serum pool overnight, 
followed by incubation with anti-human IgG peroxidase-con- 
jugated rabbit antibodies and staining with diaminobenxidine 
and peroxide. Lane ‘pMDIII’, negative control; lane 
‘pMDIIIGP, membrane-anchored version (the weak gp350- 
band may result from degraded cells); ‘pMDIIIGPTB’ and the 
following lanes, CHO clones with secreted MAversions and 
amplified as indicated with ‘-10 nM MTX’ and ‘-20 nM MTX.’ 
As described in the legend to Fig. 2, the last three lanes corre- 
spond to cells which were isolated individually (-1, -2) or 
derived from pooled colonies (-P). Amplification through MTX 
results in a strong enhancement of MA expression, but only in 
cells derived from individually isolated clones. (Panel B) A 
Coomassie blue-stained SDS-lo% polyacrylamide gel with a 
gp250/350-positive fraction was derived through molecular 
sieving chromatography. Proteins from 300 ml culture medium 
from CHO[pMDIIIGPTR-l-20 nM MTX] maintained for three 
days were concentrated by a 70% ammonium sulfate precipi- 
tation, dissolved in 30 ml 20 mM Tris . HCl pH 7.5 and separated 
by molecular sieving through Sepharose ZB-CL (Pharmacia). 
MA-positive fractions were pooled, concentrated, an aliquot was 
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brane-anchored versions, indicating that the SV40 
polyadenylation signals were used. Besides, addi- 
tional larger transcripts can be detected in the lanes 
with the MTX-amplified clones. Probably they origi- 
nate from an alternative termination downstream 
from the SV40 polyadenylation signal. Compared to 
the authentic transcripts from EBV-producing B95-8 
cells these transcripts have slightly larger sizes as a 
result from different 5’-untranslated regions. An 
additional 140 nt were contributed by SV40 and 
globin sequences. 
After selection in 20 nM MTX the two isolated 
clones have a strong amplification of the gp250/350 
transcripts whereas in cells derived from the pooled 
(20 nM MTX) colonies transcripts were almost 
undetectable. 
Fig. 3A shows an immunostained Western blot 
prepared from culture supernatant. The cells secrete 
increasing amounts of EBV proteins throughout he 
MTX selection process. The control experiment, a
Western blot with NP40 cell extracts, allows the 
identification of the glycoproteins only in cells with 
the anchored versions, indicating that the truncated 
EBV products were totally secreted. 
(c) Toxicity of the MA product 
Despite MA secretion, it seems that their high- 
level production still has negative ffects on the cells. 
Cells derived from pooled colonies after 20 nM 
MTX selection show almost no MA production after 
a two-month period in culture (Fig. 3A), as was 
already suggested by Northern blots (Fig. 2). This 
suggests that during selection in 20 nM MTX only 
the dhfr sequences were amplified in some of the 
pooled cells. These cells now have a growth advan- 
tage and displace the MA-producing cells. The 
assumption of an inhibitory effect is also supported 
by our inability to obtain a yet higher amplification 
level through increased MTX concentrations. 
analyzed by SDS-lo% PAGE, and proteins were visualized by 
Coomassie blue staining. Positions of the 200-kDa and 1ldkDa 
markers (myosin and B-galactosidase) are indicated as are the 
positions of gp250 and gp350. Due to their extensive glycosy- 
lations they appear as diffise bands. From this figure it can be 
estimated that the glycoprotein production is in the range of 
l-10 pg per lo6 cells per day. 
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Quantification of the gp250/350 production is 
difficult. Fig+ 3B shows a Coomassie blue-stained 
S~S-~lyac~l~de gel with proteins of a culture 
supernatant. The glycoprotein yield corresponds to 
the production of 5 x lo4 cells in three days and is 
estimated to be in the range of l-10 pg/106 cells per 
day. 
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